← All sarcoma trials
Recruiting now—Ages 18 Years and up

Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Sponsor: Incyte Biosciences Italy S.r.l · NCT06299553 on ClinicalTrials.gov ↗

Bring this to your care team →

Conditions studied

DLBCL - Diffuse Large B Cell Lymphoma

Where it's running1 site

1 international site

  • Incyte Biosciences Italy S.r.l

    Milan, Italy 20122

    Recruiting now
    • Nicola Battaglia(contact)+39 3429513636[email protected]
    • Mario Lapecorella(contact)[email protected]
    • Pier Luigi Zinzani(principal investigator)
    • Eliana Valentina Liardo(principal investigator)
    • Paolo Corradini(principal investigator)
    • Enrico Derenzini(principal investigator)
    • Francesca Gaia Rossi Dardanoni(principal investigator)
    • Andrès Ferreri(principal investigator)
    • Leonardo Flenghi(principal investigator)
    • Caterina Patti(principal investigator)
    • Maurizio Musso(principal investigator)
    • Annalisa Chiarenza(principal investigator)
    • Adalberto Ibatici(principal investigator)
    • Michele Spina(principal investigator)
    • Alice Di Rocco(principal investigator)
    • Maria Christina Cox(principal investigator)
    • Stefan Hohaus(principal investigator)
    • Andrea Bernardelli(principal investigator)
    • Francesco Piazza(principal investigator)
    • Domenico Pastore(principal investigator)
    • Giuseppe Tarantini(principal investigator)
    • Daniela Dessì(principal investigator)
    • Sofya Kovalchuk(principal investigator)
    • Alberto Fabbri(principal investigator)
    • Antonio Pinto(principal investigator)
    • Ferdinando Frigeri(principal investigator)
    • Mario Annunziata(principal investigator)
    • Elsa Pennese(principal investigator)
    • Caterina Cecilia Stelitano(principal investigator)
    • Mattia Novo(principal investigator)
    • Manuela Zanni(principal investigator)
    • Guido Gini(principal investigator)
See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion Criteria:

1. Patients are aged 18 years or older.
2. Patients with DLBCL R/R disease non-transplant eligible.
3. Patients who will initiate the treatment with commercially available tafasitamab and lenalidomide after the ICF signature. The decision to prescribe tafasitamab must have been made prior and regardless of the enrollment of the patient in the study.
4. Patients are able of giving the signed informed consent.

Exclusion Criteria:

1. Concomitant participation in an interventional clinical study
2. Any patient in the physician's opinion from whom initial diagnosis or follow-up data is unlikely to be obtained reliably data for the purposes of this observational study.
3. Patients who started tafasitamab treatment before signing the ICF.

Updated 2024-05-22 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.